## Clinical Context This patient has heterozygous familial hypercholesterolemia (FH) with inadequate response to moderate-intensity statin monotherapy. Current LDL-C of 450 mg/dL is far above the target of <70 mg/dL for very high-risk patients (established CAD risk equivalent). ## Stepwise Management Approach **Key Point:** Heterozygous FH requires intensive LDL-lowering therapy using combination agents, not monotherapy escalation alone. The guideline-recommended sequence for FH management is: 1. **High-intensity statin** (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) 2. **Add ezetimibe** (blocks intestinal cholesterol absorption; synergistic with statin) 3. **Add PCSK9 inhibitor** (if LDL-C target not achieved; blocks LDL receptor degradation) 4. **Apheresis** (reserved for homozygous FH or statin-intolerant heterozygous FH) ## Why Option 1 (Add Ezetimibe + PCSK9 Inhibitor) Is Correct **High-Yield:** Ezetimibe reduces LDL-C by ~18–20% and is the next logical step after statin monotherapy failure. PCSK9 inhibitors (evolocumab, alirocumab) reduce LDL-C by 40–60% and are indicated when combination statin + ezetimibe does not achieve target in heterozygous FH. **Clinical Pearl:** In heterozygous FH, the combination of statin + ezetimibe + PCSK9 inhibitor can lower LDL-C by 70–80%, achieving target in most patients without apheresis. ## Why Apheresis Is Not First-Line Apheresis is reserved for: - Homozygous FH (LDL receptor completely absent) - Statin-intolerant heterozygous FH - Heterozygous FH with established CAD despite maximal medical therapy This patient has not yet exhausted pharmacotherapy options.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.